New drugs for the treatment of inflammatory, respiratory and immunological diseases.
Griffiths
R
R
Pfizer Global R&D, Groton Laboratories, CT 06333, USA. richard_j_griffiths@groton.pfizer.com
Koch
K
K
D000818:Animals; D000911:Antibodies, Monoclonal; D018925:Chemokines / Q000037:antagonists & inhibitors; D015195:Drug Design; D004791:Enzyme Inhibitors; D006684:HLA-DR Antigens; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy*; D007249:Inflammation / Q000188:drug therapy*; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D054389:Receptors, CCR1; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors; D012140:Respiratory Tract Diseases / Q000188:drug therapy*; D048051:p38 Mitogen-Activated Protein Kinases
D000911:Antibodies, Monoclonal; C515300:CCR1 protein, human; D018925:Chemokines; D004791:Enzyme Inhibitors; D006684:HLA-DR Antigens; D054389:Receptors, CCR1; D019707:Receptors, Chemokine; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases